Sandoz to commercialise Rizmoic to treat opioid induced constipation in UK, Germany and The Netherlands
Sandoz announces that it has signed an agreement with Shionogi & Co Ltd for commercialization of Rizmoic (naldemedine) in the key European markets of Germany, the UK and the Netherlands, plus right of first refusal for certain other European markets.
Rizmoic, a once-daily 200-microgram oral tablet discovered and developed by Shionogi, is an innovative medicine indicated to treat opioid induced constipation (OIC) in adult patients previously treated with a laxative. Shionogi announced on February 22, 2019 that it had received EU marketing authorization for Rizmoic. Under the terms of the agreement, Sandoz will be responsible for commercializing Rizmoic® in Germany, the UK and the Netherlands.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.